Fortress Biotech (FBIO) vs MAIA Biotechnology (MAIA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Fortress Biotech (FBIO) has outperformed MAIA Biotechnology (MAIA) over the past year, losing 23.8% versus a loss of 29.1%. MAIA Biotechnology is the larger company by market cap ($75.3 million vs $71.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | FBIO | MAIA |
|---|---|---|
| Share price | $2.14 | $1.22 |
| Market cap | $71.20M | $75.33M |
| 1-day change | +2.15% | +6.09% |
| YTD return | -41.67% | -20.26% |
| 1-year return | -23.75% | -29.07% |
| 5-year return | -95.38% | — |
| P/E ratio (TTM) | 0.77 | — |
| Forward P/E | — | 1.10 |
| EPS (TTM) | $2.76 | $-0.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $4.53 | $3.19 |
| 52-week low | $2.00 | $0.87 |
| Distance from 52-week high | -52.87% | -61.76% |
| Analyst consensus | none | none |
| Avg. price target upside | +134.19% | +883.61% |
| Average volume | 492.39K | 527.89K |
| Shares outstanding | 33.35M | 61.74M |
| Employees | 78 | 13 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Fortress Biotech
FBIO stock →Fortress Biotech, Inc., together with its subsidiaries, operates as a biopharmaceutical company in the United States and internationally. The company offers Emrosi, a minocycline hydrochloride extended-release capsule for the treatment of rosacea; Qbrexza a medicated cloth towelette for the treatment of axillary hyperhidrosis; Accutane, an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne; Amzeeq, a minocycline topical foam for the treatment of lesions of non-nodular moderate to severe acne vulgaris; Zilxi, a minocycline topical foam for the treatment of lesions of rosacea; Exelderm, an antifungal cream for topical use; Targadox, an oral doxycycline drug for the therapy of severe acne; Luxamend, a water-based emulsion for the treatment of superficial wounds, minor cuts or scrapes, dermal ulcers, donor sites, first and second-degree burns, and radiation dermatitis; and UNLOXCYT, a death-ligand 1 blocking antibody for the treatment of metastatic cutaneous squamous cell carcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 78 employees
About MAIA Biotechnology
MAIA stock →MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC).
Health Care · Biotechnology: Pharmaceutical Preparations · 13 employees
FBIO vs MAIA FAQ
Which is bigger, Fortress Biotech or MAIA Biotechnology?
MAIA Biotechnology (MAIA) is larger, with a market capitalization of $75.33M compared with $71.20M for Fortress Biotech (FBIO).
Which stock has performed better over the past year, FBIO or MAIA?
FBIO returned -23.75% over the past 12 months, compared with -29.07% for MAIA (price return, excluding dividends). Past performance does not predict future results.
Are Fortress Biotech and MAIA Biotechnology in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.